Pharma Mar Aktie: Ungeahnte Möglichkeiten Entfalten!
Der spanische Krebsforschungsspezialist Pharma Mar verzeichnet bemerkenswerte Kursgewinne an der Börse. Die Aktie des Unternehmens konnte im vergangenen Monat um…
78,325€
-3,00%
Echtzeit-Aktienkurs Pharma Mar S.A.
Bid:
Ask:
Nachrichten zur Pharma Mar S.A. Aktie
Zepzelca® (lurbinectedin) approved by the Ministry of Health in Oman for the treatment of metastatic Small Cell Lung Cancer
Stockholm, July 21, 2023 – Immedicas product Zepzelca[®] (lurbinectedin) has received approval by the Ministry of Health in Oman for…
Klaria Year-End Report
Klaria Year-End Report 1 January–31 December 2022 Q4 2022
Summary of the Year-End Report
Successful rights issue brought 59.2 MSEK to Klaria
New collaboration…